The potential role of sphingolipid-mediated cell signaling in the interaction between hyperglycemia, acute myocardial infarction and heart failure

Bibliography

• Oswald GA, Corcoran S, Yudkin JS. Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet 1984;1:1264-7
   PubMed Web of Science ®Google Scholar
• Goode KM, John J, Rigby AS, Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart 2009;95:917-23
   Google Scholar
• Lakhdar A, Stromberg P, McAlpine SG. Prognostic importance of hyperglycaemia induced by stress after acute myocardial infarction. Br Med J (Clin Res Ed) 1984;288:288
   Google Scholar
• Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626-32
   PubMed Web of Science ®Google Scholar
• Ishihara M, Kojima S, Sakamoto T, Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J 2005;150:814-20
   PubMed Web of Science ®Google Scholar
• Domanski M, Krause-Steinrauf H, Deedwania P, The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003;42:914-22
   PubMed Web of Science ®Google Scholar
• Thrainsdottir IS, Aspelund T, Hardarson T, Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study. Eur J Cardiovasc Prev Rehabil 2005;12:465-71
   Google Scholar
• Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008;29:381-402
   PubMed Web of Science ®Google Scholar
• Egom EM, Mamas MA, Chacko S, Serum sphingolipids level as a novel potential indicator for early detection of cardiac ischemia. Circulation 2010;122:A11010
   Google Scholar
• Egom EE, Mohamed TM, Mamas MA, Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. Am J Physiol Heart Circ Physiol 2011;301:H1487-95
   Google Scholar
• Bartnik M, Ryden L, Ferrari R, The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25:1880-90
   PubMed Web of Science ®Google Scholar
• Norhammar A, Tenerz A, Nilsson G, Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-4
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Brutsaert D, Dickstein K, EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725-36
   PubMed Web of Science ®Google Scholar
• Suskin N, McKelvie RS, Burns RJ, Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000;21:1368-75
   PubMed Web of Science ®Google Scholar
• Mamas MA, Deaton C, Rutter MK, Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated? J Card Fail 2010;16:761-8
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Sturzu A, Stolarski C, The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 2004;61:297-306
   PubMed Web of Science ®Google Scholar
• Dickson RC, Lester RL. Metabolism and selected functions of sphingolipids in the yeast Saccharomyces cerevisiae. Biochim Biophys Acta 1999;1438:305-21
   PubMed Web of Science ®Google Scholar
• Perry DK, Hannun YA. The role of ceramide in cell signaling. Biochim Biophys Acta 1998;1436:233-43
   PubMed Web of Science ®Google Scholar
• Abel Lajtha GT, Goracci G. Handbook of neurochemistry and molecular neurobiology. Springer 2009;14:757
   Google Scholar
• Hannun YA, Loomis CR, Merrill AH Jr, Bell RM. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J Biol Chem 1986;261:12604-9
   PubMed Web of Science ®Google Scholar
• Goldkorn T, Dressler KA, Muindi J, Ceramide stimulates epidermal growth factor receptor phosphorylation in A431 human epidermoid carcinoma cells. Evidence that ceramide may mediate sphingosine action. J Biol Chem 1991;266:16092-7
   PubMed Web of Science ®Google Scholar
• Hannun YA, Obeid LM, Wolff RA. The novel second messenger ceramide: identification, mechanism of action, and cellular activity. Adv Lipid Res 1993;25:43-64
   PubMedGoogle Scholar
• Cavalli AG, Ligutti NM, Castro E, The role of TNFalpha and sphingolipid signaling in cardiac hypoxia: evidence that cardiomyocytes release TNFalpha and sphingosine. Basic Appl Myol 2002;12:167-75
   Google Scholar
• Bielawska AE, Shapiro JP, Jiang L, Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol 1997;151:1257-63
   PubMed Web of Science ®Google Scholar
• Thielmann M, Dorge H, Martin C, Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res 2002;90:807-13
   PubMed Web of Science ®Google Scholar
• Bielawska AE, Shapiro JP, Jiang L, Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol 1997;151:1257-63
   PubMed Web of Science ®Google Scholar
• Grosjean SA, Arstall MA, Mitchell RN, Inducible nitric oxide synthase and tumor necrosis factor in animal models of myocardial necrosis induced by coronary artery ligation or isoproterenol injection. J Card Fail 1999;5:236-45
   Google Scholar
• Aukrust P, Ueland T, Lien E, Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:376-82
   PubMed Web of Science ®Google Scholar
• Aker S, Belosjorow S, Konietzka I, Serum but not myocardial TNF-alpha concentration is increased in pacing-induced heart failure in rabbits. Am J Physiol Regul Integr Comp Physiol 2003;285:R463-9
   Web of Science ®Google Scholar
• Irwin MW, Mak S, Mann DL, Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 1999;99:1492-8
   PubMed Web of Science ®Google Scholar
• Finkel MS, Oddis CV, Jacob TD, Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9
   PubMed Web of Science ®Google Scholar
• Torre-Amione G, Kapadia S, Benedict C, Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6
   PubMed Web of Science ®Google Scholar
• Holden LA, Muller LD, Lykos T, Cassidy TW. Effect of corn silage supplementation on intake and milk production in cows grazing grass pasture. J Dairy Sci 1995;78:154-60
   Google Scholar
• Oral H, Dorn GW II, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem 1997;272:4836-42
   PubMed Web of Science ®Google Scholar
• Egom EE, Ke Y, Solaro RJ, Lei M. Cardioprotection in ischemia/reperfusion injury: spotlight on sphingosine-1-phosphate and bradykinin signalling. Prog Biophys Mol Biol 2010;103:142-7
   Google Scholar
• Yatomi Y, Igarashi Y, Yang L, Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem 1997;121:969-73
   PubMed Web of Science ®Google Scholar
• Yatomi Y, Ozaki Y, Ohmori T, Igarashi Y. Sphingosine 1-phosphate: synthesis and release. Prostaglandins 2001;64:107-22
   PubMed Web of Science ®Google Scholar
• English D, Welch Z, Kovala AT, Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. Faseb J 2000;14:2255-65
   PubMed Web of Science ®Google Scholar
• Pappu R, Schwab SR, Cornelissen I, Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007;316:295-8
   PubMed Web of Science ®Google Scholar
• Ito K, Anada Y, Tani M, Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem Biophys Res Commun 2007;357:212-17
   PubMed Web of Science ®Google Scholar
• Hanel P, Andreani P, Graler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. Faseb J 2007;21:1202-9
   PubMed Web of Science ®Google Scholar
• Ancellin N, Colmont C, Su J, Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem 2002;277:6667-75
   PubMed Web of Science ®Google Scholar
• Spiegel S, Milstien S. Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by divergent pathways. Biochem Soc Trans 2003;31:1216-19
   PubMed Web of Science ®Google Scholar
• Van Brocklyn JR, Lee MJ, Menzeleev R, Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J Cell Biol 1998;142:229-40
   PubMed Web of Science ®Google Scholar
• Rosenfeldt HM, Hobson JP, Maceyka M, EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration. Faseb J 2001;15:2649-59
   PubMed Web of Science ®Google Scholar
• Alewijnse AE, Peters SL, Michel MC. Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br J Pharmacol 2004;143:666-84
   PubMed Web of Science ®Google Scholar
• Czyborra C, Bischoff A, Michel MC. Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine. Naunyn Schmiedebergs Arch Pharmacol 2006;373:37-44
   Google Scholar
• Hemmings DG. Signal transduction underlying the vascular effects of sphingosine 1-phosphate and sphingosylphosphorylcholine. Naunyn Schmiedebergs Arch Pharmacol 2006;373:18-29
   PubMed Web of Science ®Google Scholar
• Knapp M, Baranowski M, Czarnowski D, Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction. Med Sci Monit 2009;15:CR490-3
   PubMed Web of Science ®Google Scholar
• Budde K, Schutz M, Glander P, FTY720 (fingolimod) in renal transplantation. Clin Transplant 2006;20(Suppl 17):17-24
   PubMedGoogle Scholar
• Egom EE, Ke Y, Musa H, FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol 2010;48:406-14
   PubMed Web of Science ®Google Scholar
• Schlitt A, Blankenberg S, Yan D, Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab 2006;3:5
   Google Scholar
• Turinsky J, O'Sullivan DM, Bayly BP. 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J Biol Chem 1990;265:16880-5
   PubMed Web of Science ®Google Scholar
• Lee JS, Pinnamaneni SK, Eo SJ, Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites. J Appl Physiol 2006;100:1467-74
   PubMed Web of Science ®Google Scholar
• Straczkowski M, Kowalska I, Nikolajuk A, Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 2004;53:1215-21
   PubMed Web of Science ®Google Scholar
• Dobrzyn A, Knapp M, Gorski J. Effect of acute exercise and training on metabolism of ceramide in the heart muscle of the rat. Acta Physiol Scand 2004;181:313-19
   PubMedGoogle Scholar
• Collier CA, Bruce CR, Smith AC, Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am J Physiol Endocrinol Metab 2006;291:E182-9
   PubMed Web of Science ®Google Scholar
• An D, Kewalramani G, Chan JK, Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3. Diabetologia 2006;49:2174-84
   Google Scholar
• Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 1997;105:187-95
   PubMed Web of Science ®Google Scholar
• Laychock SG, Tian Y, Sessanna SM. Endothelial differentiation gene receptors in pancreatic islets and INS-1 cells. Diabetes 2003;52:1986-93
   PubMed Web of Science ®Google Scholar
• Ban K, Noyan-Ashraf MH, Hoefer J, Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340-50
   PubMed Web of Science ®Google Scholar
• Noyan-Ashraf MH, Momen MA, Ban K, GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975-83
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Elahi D, Hentosz T, Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004;110:955-61
   PubMed Web of Science ®Google Scholar
• Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 2007;21:253-6
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Mankad S, Sokos GG, Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-5
   PubMed Web of Science ®Google Scholar
• Sokos GG, Nikolaidis LA, Mankad S, Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-9
   PubMed Web of Science ®Google Scholar
• Whiteman EL, Cho CH, Birnbaum MJ. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab 2002;13:444-51
   PubMed Web of Science ®Google Scholar
• Alessi DR, Deak M, Casamayor A, 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 1997;7:776-89
   PubMed Web of Science ®Google Scholar
• Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9:59-71
   PubMed Web of Science ®Google Scholar
• Hill MM, Clark SF, Tucker DF, A role for protein kinase Bbeta/Akt2 in insulin-stimulated GLUT4 translocation in adipocytes. Mol Cell Biol 1999;19:7771-81
   PubMedGoogle Scholar
• Jiang ZY, Zhou QL, Coleman KA, Insulin signaling through Akt/protein kinase B analyzed by small interfering RNA-mediated gene silencing. Proc Natl Acad Sci USA 2003;100:7569-74
   PubMed Web of Science ®Google Scholar
• Cho H, Mu J, Kim JK, Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001;292:1728-31
   PubMed Web of Science ®Google Scholar
• Summers SA, Garza GL, Zhou H, Birnbaum MJ. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 1998;18:5457-64
   PubMed Web of Science ®Google Scholar
• Holland WL, Brozinick JT, Wang LP, Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007;5:167-79
   PubMed Web of Science ®Google Scholar
• Ma MM, Chen JL, Wang GG, Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice. Diabetologia 2007;50:891-900
   PubMed Web of Science ®Google Scholar
• Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002;9:387-99
   PubMed Web of Science ®Google Scholar
• Rapizzi E, Taddei ML, Fiaschi T, Sphingosine 1-phosphate increases glucose uptake through trans-activation of insulin receptor. Cell Mol Life Sci 2009;66:3207-18
   PubMed Web of Science ®Google Scholar
• Murphy E, Steenbergen C. Does inhibition of glycogen synthase kinase protect in mice? Circ Res 2008;103:226-8
   Google Scholar
• Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36
   PubMed Web of Science ®Google Scholar
• Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in cardioprotection. J Cardiovasc Pharmacol 2009;53:189-97
   PubMed Web of Science ®Google Scholar
• Vessey DA, Li L, Kelley M, Karliner JS. Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia. Biochem Biophys Res Commun 2008;375:425-9
   Web of Science ®Google Scholar
• Park TS, Hu Y, Noh HL, Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008;49:2101-12
   PubMed Web of Science ®Google Scholar
• Holland WL, Brozinick JT, Wang LP, Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007;5:167-79
   PubMed Web of Science ®Google Scholar
• Yeh CC, Li H, Malhotra D, Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction. Am J Physiol Heart Circ Physiol 2009;296:H1193-9
   Google Scholar
• Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009;82:201-11
   Google Scholar